Catalyst Dossier · compiled by CeliA 🧫
Laboratorios Farmaceuticos Rovi, S.A./ADR (LRVIY)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2026-12-31 (est.)Phase 3 · Etoricoxib + Betamethasone fixed doseimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Chlorthalidone 25 mg + amiloride hydrochloride 5 mg | Phase 3 | Arterial Hypertension |
| Depigoid Parietaria judaica 1000DPP/ml | Phase 3 | Allergic Rhinoconjunctivitis |
| Glucosamine and chondroitin sulfate combination (Eurofarma) | Phase 3 | Osteoarthritis of Knee |
| Minoxidil Topical Foam | Phase 3 | Alopecia |
| Study group - quadrivalent recombinant hemagglutinin influenza vaccine | Phase 3 | Influenza, Human |
| Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control | Phase 2 | Allergy to Grass Pollen (Dactylis Glomerata) |
| DP/MG/14-1 | Phase 2 | Rhinitis |
| Losartan/Chlorthalidone in fixed dose | Phase 3 | Essential Arterial Hypertension |
| 1 (Dose Response Skin Prick Tests) | Phase 2 | Cat Allergy (Disorder) |
| Etoricoxib + Tizanidine fixed dose | Phase 3 | Acute Low-back Pain |
| Levetiracetam | Phase 3 | Epilepsy |
| Grass pollen allergenic extract (L. perenne-C. dactylon ) | Phase 2 | Allergic Rhinoconjunctivitis |
| Candicort® | Phase 3 | Tinea |
| Cupressus arizonica | Phase 2 | Allergy to Tree Pollen |
| Glucosamine sulphate and chondroitin sulphate association | Phase 3 | Osteoarthritis of the Knee |
| Group 1 | Phase 3 | Nasal Congestion and Inflammations |
| Four different concentrations of Poa pratensis allergen extract, positive control and negative control | Phase 2 | Allergy to Grass Pollen |
| Sodium picosulphate, light magnesium oxide and anhydride citric acid. | Phase 3 | Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time. |
| four differente concentrations of Alternaria alternata allergen extract, positive control and negative control | Phase 2 | Allergy to Alternaria Fungus |
| Immunotherapy with modified extract of Olea europaea pollen | Phase 3 | Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LRVIY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.